MA-BOARD-INTERNATIONAL
Board International, the all-in-one Board Decision-Making Platform vendor, today announced strong Q2 2021 performance, achieving a 45% increase in ARR across the last 12 months.
The company experienced robust levels of growth in Q2 2021, which included a 58% increase in new Software ARR orders compared to the same quarter last year, contributing to a 69% increase in H1 2021. Board has more than 3,000 customers worldwide and welcomed 54 new brands in Q2 2021, including Jhpiego, Zentiva, Evergreen Environmental, and Luye Pharma. Additionally, Board registered a Net Retention Rate of 114%.
During the second quarter of the year, Board announced the addition of Marco Limena to its Board of Directors as Non-Executive Director and Senior Advisor. The company has also hired more than 125 people since the beginning of the year, growing its employee base by 15% to reach a total headcount of 500 employees across 25 countries. These new hires include various industry leaders and experts, including Mr. Christof Majer as Global VP of Alliances & Channel, who will lead partner business strategy, and Mr. Marcel Doppenberg as Sales Director for the Benelux Region, who will drive local growth.
On April 28, Board released Board Spring 21, the latest version of its market-leading Decision-Making Platform. The new version represents a great milestone in the evolution of Board’s technology and empowers organizations to access supercharged performance, unmatched flexibility, rock-solid reliability, and a seamless upgrade path from previous versions. Board continues to replace legacy applications and spreadsheets, driving a new era of decision-making, helping enterprises succeed in a constantly changing reality through greater planning agility and more accurate insights.
During the second quarter, Board also continued to strengthen its position as a leading provider of unified Business Intelligence, Planning, and Predictive Analytics, and its value proposition received significant attention from analysts. Board International was recognized as a March 2021 Gartner Peer Insights Customers’ Choice for Cloud Financial Planning and Analysis (FP&A) Solutions, confirmed as a Market Leader with the Best Portfolio Capabilities in Integrated Planning & Analytics by BARC, and named a Leader in the Customer Experience and Vendor Credibility models in Dresner Advisory’s 2021 Wisdom of Crowds Market Study for both BI and EPM.
"I am very proud of these results, for which I want to congratulate the entire Board team. Our flexible, all-in-one Decision-Making Platform gives organizations a strong competitive advantage. It is the perfect choice for functional planning requirements and also for achieving the ideal state of unifying planning across the enterprise," comments Maurizio Carli, CEO of Board International. "In the second half of the year, we will continue focusing on product innovation to enhance our customer experience and support growing market demand."
About Board
Board is the #1 Decision-Making Platform. Founded in 1994, Board International enables people to have a transformative impact on their business, helping them to intuitively leverage their data in a flexible, all-in-one environment. By unifying Business Intelligence, Planning, and Predictive Analytics, the Board platform allows companies to produce a single, accurate, and complete view of business information, gain actionable insights, and achieve full control of performance across the entire organization. Thanks to Board, global enterprises such as M&S, Coca-Cola, Ricoh, KPMG, Puma, Siemens, and ZF Group have deployed end-to end decision-making applications at a fraction of the time and cost associated with traditional solutions. www.board.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005826/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
